Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded Cepheid and Myriad Genetics and reinstated Thermo Fisher Scientific as the investment firm revised estimates on a number of life science tools and molecular diagnostics vendors.

In a research report, analyst Isaac Ro upgraded Cepheid to a Buy rating, Myriad to Neutral, and reinstated Thermo Fisher at a Buy rating.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.